Table 1.

Experimental parameters for combination immunotherapy of MOF-gated MS vaccination and PD-1 blockade (Figs. 5, 6 and S31–S34).

Group	Sample administered (s.c.)	Dose (/mouse, s.c.)	Dose (/mouse, i.p.)
a	Free OVA	OVA (100 μg)	Anti-PD-1 Ab (200 μg)
b	Free OVA	OVA (100 μg)	–
c	Free OVA	OVA (100 μg)	Anti-PD-1 Ab (20 μg)
d	OVAonMS	OVA, 100 μg; MS, 600 μg	Anti-PD-1 Ab (20 μg)
e	OVA/polyIConMS	OVA, 100 μg; polyIC, 100 μg; MS, 600 μg	Anti-PD-1 Ab (20 μg)
f	(MS@OVAinMOF)@(polyICinMOF)	OVA, 100 μg; polyIC, 100 μg; MS@MOF, 600 μg	Anti-PD-1 Ab (20 μg)
g	OVAonMS	OVA, 100 μg; MS, 600 μg	Anti-PD-1 Ab (200 μg)
h	OVA/polyIConMS	OVA, 100 μg; polyIC, 100 μg; MS, 600 μg	Anti-PD-1 Ab (200 μg)
i	(MS@OVAinMOF)@(polyICinMOF)	OVA, 100 μg; polyIC, 100 μg; MS@MOF, 600 μg	Anti-PD-1 Ab (200 μg)